BMC Cancer (Oct 2010)

Low salivary testosterone levels in patients with breast cancer

  • Tsigginou Alexandra,
  • Marinopoulos Spyros,
  • Zava David,
  • Dimitrakakis Constantine,
  • Antsaklis Aris,
  • Glaser Rebecca

DOI
https://doi.org/10.1186/1471-2407-10-547
Journal volume & issue
Vol. 10, no. 1
p. 547

Abstract

Read online

Abstract Background Correlation between circulating sex steroid levels and breast cancer has been controversial, with measurement of free, or bioavailable hormone rarely available. Salivary hormone levels represent the bioavailable fraction. To further elucidate the role of endogenous hormones in breast cancer, we aimed to assess correlation between salivary sex steroid levels and breast cancer prevalence. Methods Salivary hormone levels of testosterone (T), Estradiol (E2), Progesterone (P), Estriol (E3), Estrone (E1), DHEAS and Cortisol (C) were measured by Enzyme Immunoassay (EIA) in 357 women with histologically verified breast cancer and 184 age-matched control women. Results Salivary T and DHEAS levels were significantly lower in breast cancer cases vs. controls (27.2+13.9 vs. 32.2+17.5 pg/ml, p Conclusions Salivary T levels, representing the bioavailable hormone, are significantly lower in women with breast cancer compared to age-matched control women. These findings support the protective role of biovailable testosterone in counteracting the proliferative effects of estrogens on mammary tissue.